Results 231 to 240 of about 56,774 (264)
Some of the next articles are maybe not open access.
Immunomonitoring measures in relapsing-remitting multiple sclerosis
Journal of Neuroimmunology, 2004Forty-five patients with relapsing-remitting multiple sclerosis (MS) were examined to determine intracellular cytokine profiles and the surface phenotype of circulating lymphocytes during active, recovery, and stable stages. Active stage patients were characterized by decreases in CD4(+)IL-4(+) Th2 as well as CD4(+)IFN-gamma(+) Th1 cells, when compared
Makoto, Matsui +4 more
openaire +2 more sources
Immunologic therapy for relapsing-remitting multiple sclerosis
Current Neurology and Neuroscience Reports, 2001The treatment of relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis, has been revolutionized in recent years. In addition to effective treatment of acute relapses, therapies are now available to prevent relapses, reduce the burden of disease as seen on magnetic resonance imaging, and possibly even slow the course ...
H J, MacLean, M S, Freedman
openaire +2 more sources
Oral fumarate for relapsing-remitting multiple sclerosis
The Lancet, 2008Udgivelsesdato: 2008/10 ...
Sorensen, P.S., Sellebjerg, F.
openaire +2 more sources
Natalizumab in relapsing-remitting multiple sclerosis
Expert Review of Neurotherapeutics, 2016Natalizumab is the first humanized moclonal antibody indicated in the treatment of relapsing-remitting multiple sclerosis (RRMS). Based on its remarkable efficacy in reducing disease activity and reducing the risk of disability progession in RRMS, and the risk of a serious adverse event (progressive multifocal leukoencephalopathy [PML]), natalizumab ...
openaire +2 more sources
Emerging Therapies in Relapsing-Remitting Multiple Sclerosis
Reviews on Recent Clinical Trials, 2010Disease modifying therapy (DMT) first became available for relapsing-remitting multiple sclerosis (RRMS) fifteen years ago with the development of the moderately effective injectable agents interferon (IFN)-beta and glatiramer acetate (GA). The subsequent licensure of mitoxantrone (MX) and natalizumab (NZ) has allowed for better control of refractory ...
James J, Marriott, Paul W, O'Connor
openaire +2 more sources
Mycophenolate mofetil for relapsing-remitting multiple sclerosis
Cochrane Database of Systematic Reviews, 2012Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system and a leading cause of disability in young and middle-aged adults. Mycophenolate mofetil (MMF) is an immunosuppressive agent that has been used for the prevention of allograft rejection after renal, cardiac, or liver transplant and in patients with autoimmune diseases ...
Yousheng, Xiao +3 more
openaire +2 more sources
Social Cognition Impairments in Relapsing-Remitting Multiple Sclerosis
Journal of the International Neuropsychological Society, 2011AbstractTheory of Mind (ToM) is the ability to attribute independent mental states to self and others to explain and predict behavior. Impairment of ToM is well established in developmental pathologies. In neurological populations, investigation of ToM is still rare but data suggest that ToM impairment could contribute to behavioral and social ...
Henry, A. +5 more
openaire +3 more sources
Relapsing-Remitting Multiple Sclerosis
BioDrugs, 2000Multiple sclerosis is now a treatable disease and several immunomodulating therapies exist, but their clinical efficacy is moderate and treatment failure during the course of the disease is an increasing problem. As agents with different targets are available, the question was raised whether combination of these therapies would: be safe;result in ...
M, Mäurer, P, Rieckmann
openaire +2 more sources
Alemtuzumab for relapsing-remitting multiple sclerosis
The Lancet Neurology, 2014Richard A, Diaz +4 more
openaire +2 more sources